Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future
Alisa Likhitsup, Nataliya Razumilava, Neehar D. Parikh – 21 February 2019
Hepatocellular Carcinoma Risk After Direct‐Acting Antiviral Therapy
Feng Su, George N. Ioannou – 21 February 2019
Hepatocellular Carcinoma Risk After Direct‐Acting Antiviral Therapy
Feng Su, George N. Ioannou – 21 February 2019
Phenobarbital‐Induced Liver Injury With Nodal Angiomatosis
Li‐Ting Cheng, Matthew M. Yeh, Chun‐Chi Lu – 21 February 2019
What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?
Neil Mehta, Francis Y. Yao – 21 February 2019
Hepatocellular Carcinoma Risk After Direct‐Acting Antiviral Therapy
Feng Su, George N. Ioannou – 21 February 2019
Surveillance and Diagnosis of Hepatocellular Carcinoma
Jane Lim, Amit G. Singal – 21 February 2019
The Spectrum of Hepatic Involvement in Patients With Telomere Disease
Devika Kapuria, Gil Ben‐Yakov, Rebecca Ortolano, Min Ho Cho, Or Kalchiem‐Dekel, Varun Takyar, Shilpa Lingala, Naveen Gara, Michele Tana, Yun Ju Kim, David E. Kleiner, Neal S. Young, Danielle M. Townsley, Christopher Koh, Theo Heller – 21 February 2019 – Loss‐of‐function mutations in genes that encode for components of the telomere repair complex cause accelerated telomere shortening. Hepatic involvement has been recognized as a cause of morbidity in telomere diseases, but very few studies have characterized the nature and extent of liver involvement in affected patients.